OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
Poviztra is a second brand of Wegovy
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
The new plant will manufacture high-quality Type I borosilicate glass tubing
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Subscribe To Our Newsletter & Stay Updated
